Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

被引：137

作者：

de Jonge, Marthe M. ^{[1
]}

Auguste, Aurelie ^{[2
]}

van Wijk, Lise M. ^{[3
]}

Schouten, Philip C. ^{[1
]}

Meijers, Matty ^{[3
]}

ter Haar, Natalja T. ^{[1
]}

Smit, Vincent T. H. B. M. ^{[1
]}

Nout, Remi A. ^{[4
]}

Glaire, Mark A. ^{[5
]}

Church, David N. ^{[5
,6
]}

Vrieling, Harry ^{[3
]}

Job, Bastien ^{[7
]}

Boursin, Yannick ^{[2
]}

de Kroon, Cor D. ^{[8
]}

Rouleau, Etienne ^{[9
]}

Leary, Alexandra ^{[2
,10
]}

Vreeswijk, Maaike P. G. ^{[3
]}

Bosse, Tjalling ^{[1
]}

机构：

[1] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands

[2] Gustave Roussy Canc Ctr, INSERM, U981, Villejuif, France

[3] Leiden Univ, Dept Human Genet, Med Ctr, Leiden, Netherlands

[4] Leiden Univ, Dept Radiotherapy, Med Ctr, Leiden, Netherlands

[5] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England

[6] Oxford Univ Hosp NHS Fdn Trust, Oxford Biomed Res Ctr, John Radcliffe Hosp, NIHR, Oxford, England

[7] UMS AMMICA, Gustave Roussy Canc Ctr, Plateforme Bioinformat, Villejuif, France

[8] Leiden Univ, Dept Gynecol, Med Ctr, Leiden, Netherlands

[9] Gustave Roussy Canc Ctr, Dept Genet, Villejuif, France

[10] Gustave Roussy Canc Ctr, Dept Med Oncol, Villejuif, France

来源：

CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 03期

基金：

英国惠康基金;

关键词：

CLEAR-CELL; MAINTENANCE THERAPY; SOMATIC MUTATIONS; OPEN-LABEL; CANCER; OVARIAN; PLATINUM; PREDICT; CHEMOTHERAPY; SURVIVAL;

D O I：

10.1158/1078-0432.CCR-18-1443

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: The elevated levels of somatic copy-number alterations (SCNAs) in a subset of high-risk endometrial cancers are suggestive of defects in pathways governing genome integrity. We sought to assess the prevalence of homologous recombination deficiency (HRD) in endometrial cancers and its association with histopathologic and molecular characteristics. Experimental Design: Fresh tumor tissue was prospectively collected from 36 endometrial cancers, and functional HRD was examined by the ability of replicating tumor cells to accumulate RAD51 protein at DNA double-strand breaks (RAD51 foci) induced by ionizing radiation. Genomic alterations were determined by next-generation sequencing and array comparative genomic hybridization/SNP array. The prevalence of BRCA-associated genomic scars, a surrogate marker for HRD, was determined in the The Cancer Genome Atlas (TCGA) endometrial cancer cohort. Results: Most endometrial cancers included in the final analysis (n = 25) were of non-endometrioid (52%), grade 3 (60%) histology, and FIGO stage I (72%). HRD was observed in 24%(n = 6) of cases and was restricted to non-endometrioid endometrial cancers (NEEC), with 46% of NEECs being HRD compared with none of the endometrioid endometrial cancers (EEC, P = 0.014). All but 1 of the HRD cases harbored either a pathogenic BRCA1 variant or high somatic copy-number (SCN) losses of HR genes. Analysis of TCGA cases supported these results, with BRCA-associated genomic scars present in up to 48% (63/132) of NEEC versus 12% (37/312) of EEC (P < 0.001). Conclusions: HRD occurs in endometrial cancers and is largely restricted to non-endometrioid, TP53-mutant endometrial cancers. Evaluation of HRD may help select patients that could benefit from treatments targeting this defect, including platinum compounds and PARP inhibitors.

引用

页码：1087 / 1097

页数：11

共 54 条

[11] ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer Diagnosis, Treatment and Follow-up [J].

Colombo, Nicoletta ;

Creutzberg, Carien ;

Amant, Frederic ;

Bosse, Tjalling ;

Gonzalez-Martin, Antonio ;

Ledermann, Jonathan ;

Marth, Christian ;

Nout, Remi ;

Querleu, Denis ;

Mirza, Mansoor Raza ;

Sessa, Cristiana .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (01) :2-30

[12] RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer [J].

Cruz, C. ;

Castroviejo-Bermejo, M. ;

Gutierrez-Enriquez, S. ;

Llop-Guevara, A. ;

Ibrahim, Y. H. ;

Gris-Oliver, A. ;

Bonache, S. ;

Morancho, B. ;

Bruna, A. ;

Rueda, O. M. ;

Lai, Z. ;

Polanska, U. M. ;

Jones, G. N. ;

Kristel, P. ;

de Bustos, L. ;

Guzman, M. ;

Rodriguez, O. ;

Grueso, J. ;

Montalban, G. ;

Caratu, G. ;

Mancuso, F. ;

Fasani, R. ;

Jimenez, J. ;

Howat, W. J. ;

Dougherty, B. ;

Vivancos, A. ;

Nuciforo, P. ;

Serres-Creixams, X. ;

Rubio, I. T. ;

Oaknin, A. ;

Cadogan, E. ;

Barrett, J. C. ;

Caldas, C. ;

Baselga, J. ;

Saura, C. ;

Cortes, J. ;

Arribas, J. ;

Jonkers, J. ;

Diez, O. ;

O'Connor, M. J. ;

Balmana, J. ;

Serra, V .

ANNALS OF ONCOLOGY, 2018, 29 (05) :1203-1210

[13] HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures [J].

Davies, Helen ;

Glodzik, Dominik ;

Morganella, Sandro ;

Yates, Lucy R. ;

Staaf, Johan ;

Zou, Xueqing ;

Ramakrishna, Manasa ;

Martin, Sancha ;

Boyault, Sandrine ;

Sieuwerts, Anieta M. ;

Simpson, Peter T. ;

King, Tari A. ;

Raine, Keiran ;

Eyfjord, Jorunn E. ;

Kong, Gu ;

Borg, Ake ;

Birney, Ewan ;

Stunnenberg, Hendrik G. ;

van de Vijver, Marc J. ;

Borresen-Dale, Anne-Lise ;

Martens, John W. M. ;

Span, Paul N. ;

Lakhani, Sunil R. ;

Vincent-Salomon, Anne ;

Sotiriou, Christos ;

Tutt, Andrew ;

Thompson, Alastair M. ;

Van Laere, Steven ;

Richardson, Andrea L. ;

Viari, Alain ;

Campbell, Peter J. ;

Stratton, Michael R. ;

Nik-Zainal, Serena .

NATURE MEDICINE, 2017, 23 (04) :517-+

[14] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial [J].

de Boer, Stephanie M. ;

Powell, Melanie E. ;

Mileshkin, Linda ;

Katsaros, Dionyssios ;

Bessette, Paul ;

Haie-Meder, Christine ;

Ottevanger, Petronella B. ;

Ledermann, Jonathan A. ;

Khaw, Pearly ;

Colombo, Alessandro ;

Fyles, Anthony ;

Baron, Marie-Helene ;

Jurgenliemk-Schulz, Ina M. ;

Kitchener, Henry C. ;

Nijman, Hans W. ;

Wilson, Godfrey ;

Brooks, Susan ;

Carinelli, Silvestro ;

Provencher, Diane ;

Hanzen, Chantal ;

Lutgens, Ludy C. H. W. ;

Smit, Vincent T. H. B. M. ;

Singh, Naveena ;

Do, Viet ;

D'Amico, Romerai ;

Nout, Remi A. ;

Feeney, Amanda ;

Verhoeven-Adema, Karen W. ;

Putter, Hein ;

Creutzberg, Carien L. .

LANCET ONCOLOGY, 2018, 19 (03) :295-309

[15] Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report [J].

de Jonge, M. M. ;

Mooyaart, A. L. ;

Vreeswijk, M. P. G. ;

de Kroon, C. D. ;

van Wezel, T. ;

van Asperen, C. J. ;

Smit, V. T. H. B. M. ;

Dekkers, O. M. ;

Bosse, T. .

EUROPEAN JOURNAL OF CANCER, 2017, 72 :215-225

[16] The genetic landscape of endometrial clear cell carcinomas [J].

DeLair, Deborah F. ;

Burke, Kathleen A. ;

Selenica, Pier ;

Lim, Raymond S. ;

Scott, Sasinya N. ;

Middha, Sumit ;

Mohanty, Abhinita S. ;

Cheng, Donavan T. ;

Berger, Michael F. ;

Soslow, Robert A. ;

Weigelt, Britta .

JOURNAL OF PATHOLOGY, 2017, 243 (02) :230-241

[17] Integrated genomic characterization of endometrial carcinoma [J].

Getz, Gad ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Lander, Eric ;

Sivachenko, Andrey ;

Sougnez, Carrie ;

Lawrence, Mike ;

Kandoth, Cyriac ;

Dooling, David ;

Fulton, Robert ;

Fulton, Lucinda ;

Kalicki-Veizer, Joelle ;

McLellan, Michael D. ;

O'Laughlin, Michelle ;

Schmidt, Heather ;

Wilson, Richard K. ;

Ye, Kai ;

Ding, Li ;

Mardis, Elaine R. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Lee, Darlene ;

Li, Haiyan I. ;

Marra, Marco A. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Plettner, Patrick ;

Schein, Jacqueline E. ;

Sipahimalani, Payal ;

Tam, Angela ;

Varhol, Richard J. ;

Robertson, A. Gordon ;

Pashtan, Itai ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Schumacher, Steven E. ;

Tabak, Barbara .

NATURE, 2013, 497 (7447) :67-73

[18] Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma [J].

Gilks, C. Blake ;

Oliva, Esther ;

Soslow, Robert A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2013, 37 (06) :874-881

[19] Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor [J].

Gockley, Allison A. ;

Kolin, David L. ;

Awtrey, Christopher S. ;

Lindeman, Neal I. ;

Matulonis, Ursula A. ;

Konstantinopoulos, Panagiotis A. .

GYNECOLOGIC ONCOLOGY, 2018, 150 (02) :219-226

[20] A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer [J].

Graeser, Monika ;

McCarthy, Afshan ;

Lord, Christopher J. ;

Savage, Kay ;

Hills, Margaret ;

Salter, Janine ;

Orr, Nicholas ;

Parton, Marina ;

Smith, Ian E. ;

Reis-Filho, Jorge S. ;

Dowsett, Mitch ;

Ashworth, Alan ;

Turner, Nicholas C. .

CLINICAL CANCER RESEARCH, 2010, 16 (24) :6159-6168

← 1 2 3 4 5 6 →